Ocugen Inc OCGN
NASDAQ · United States · Health Technology
$1.02+0.02 (+2.00%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific conferences. Euretina Innovation Spotlight (EIS) 2026Location: VIECON, Vienna, AustriaDate: Wednesday, September 30, 2026Time: 2:34 p.m. CESTFormat: Company presentationTitle: Ocugen Company Over
Recently published Retinitis Pigmentosa Market Insights report includes a comprehensive understanding of current treatment practices, retinitis pigmentosa emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of its executive leadership team will present at two upcoming investor and industry conferences. H.C. Wainwright: Biotech on Tap 2026Location: EY Auditorium, Munich, GermanyDate: Thursday, October 1, 2026Time: 1:45–2:30 p.m. CESTFormat: Panel discussionTitle: Structured Finance Solut
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.